Key result
Landiolol safely accelerates HR reduction and early symptom improvement vs standard therapy in acute HFrEF.
Why the study?
Rate control of atrial fibrillation in acute heart failure with reduced LVEF is challenging and requires evaluation of intensive rate control strategies.
Does intensive rate control with landiolol and digoxin improve heart rate reduction in patients with acute heart failure and atrial fibrillation?
RCT (n=40)
Does intensive rate control with landiolol and digoxin improve heart rate reduction in patients with acute heart failure and atrial fibrillation?
In patients with acute heart failure and reduced LVEF, landiolol-based intensive rate control provides faster and safe heart rate reduction with early symptomatic benefit compared to standard therapy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Justifies protocolized landiolol use in AHF with reduced LVEF and AF; extends safe beta-blocker options in decompensated HF.
AIMS: Rate control of atrial fibrillation (AF) in acute heart failure (AHF) with reduced left ventricular ejection fraction (LVEF) is challenging. We evaluated the safety and efficacy of intensive rate control (IRC) using landiolol with adjunctive digoxin. METHODS AND RESULTS: Forty patients with AHF due to AF [heart rate (HR) > 130/min, LVEF <40%] were randomized to IRC with landiolol plus digoxin or standard rate control therapy. The primary endpoint was sustained HR reduction >20% or <115/min at 2 h. Haemodynamics, dyspnoea, and lung congestion were assessed serially. HR control was achieved faster in the IRC vs. standard group (median 1.5 vs. 4 h; P = 0.016). At 2 h, HR decreased by 40% of the IRC group vs. 23% of standard therapy group (P = 0.045), and the primary endpoint was reached in 80% vs. 20% of the patients, respectively (P = 0.04). IRC resulted in greater dyspnoea relief and lung decongestion without excess hypotension or adverse events. At 24 h, outcomes between the groups were similar. CONCLUSION: In AHF with reduced LVEF, protocolized landiolol-based intensive rate control provides faster and safe HR reduction with early symptomatic benefit compared with standard therapy. Pre-registered Clinical Trial Number: ClinicalTrials.org: NCT04694092.
Šramko et al. (2026) conducted an RCT in Acute heart failure due to atrial fibrillation (n=40). Landiolol plus digoxin vs. Standard rate control therapy was evaluated on Sustained HR reduction >20% or <115/min at 2 h (p=0.04). Intensive rate control using landiolol plus digoxin achieved sustained heart rate reduction at 2 hours in 80% of patients with acute heart failure compared to 20% with standard therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: